New insider activity at Supernus Pharmaceuticals ( (SUPN) ) has taken place on September 30, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
President & CEO Jack Khattar has sold 10,235 shares of Supernus Pharmaceuticals stock, amounting to a total sale value of $491,484.
Spark’s Take on SUPN Stock
According to Spark, TipRanks’ AI Analyst, SUPN is a Outperform.
Supernus Pharmaceuticals demonstrates strong financial health and operational efficiency, supported by robust earnings call highlights. However, technical indicators suggest overbought conditions, and the valuation appears stretched. The company’s future growth potential, driven by strategic acquisitions and product launches, is a significant positive factor.
To see Spark’s full report on SUPN stock, click here.
More about Supernus Pharmaceuticals
YTD Price Performance: 30.66%
Average Trading Volume: 815,231
Technical Sentiment Signal: Buy
Current Market Cap: $2.67B